Abstract
(Abstracted from J Clin Oncol 2020;38:3468–3493) Despite advances in diagnosis and therapy, an individual with ovaries carries an approximate 1 in 108 lifetime chance to die due to ovarian cancer (OC). Primary therapy typically involves surgical cytoreduction and a combination regimen of platinum and a taxane.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
